Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

...

Page Properties
idtag

Author

  • Alfred Hassig

  • Heinrich Kremer

  • Stefan Lanka

  • Liang Wen-Xi

  • Kurt Stampfli

Publisher

  • -

Category

  • Cause of AIDS

Topic

  • Real Cause of AIDS

Article Type

  • Editorial Article

Publish Year

  • 1998

Page Properties
idmeta

Meta Description

  • Study suggests AIDS is not a viral venereal disease but an inflammatory autoimmune process. Misinterpretation of this has led to continuous failure in AIDS treatment.

Summary

  • This editorial article discusses the misinterpretation of AIDS as a viral venereal disease instead of an inflammatory autoimmune process. It suggests that the specificity of the anti-HIV antibody test needs to be re-evaluated. The article proposes that the treatment of AIDS should focus on providing the body with sufficient amounts of antioxidative and antiproteolytic phyto-phenolic mixtures found in teas and spices. It also highlights the toxicity of certain drugs used in AIDS treatment and the importance of addressing nutritional deficiencies. The article emphasizes the role of polyphenols, tannins, and flavonoids as protective substances against external influences. Overall, the article argues for a reevaluation of the current approach to AIDS prevention and treatment.

Meta Tag

  • AIDS

  • Flavonoids

  • Tannins

  • Antioxidative

  • Phyto-phenolic mixtures

  • Metabolism

  • Inflammation

  • Stress-induced

  • Nutritional supply

  • Catabolic states

  • Autoimmune diseases

  • HIV

Featured Image

Featured Image Alt Tag

  • Keyword of the image

By A. Hässig, H. Kremer, S. Lanka, W-X Liang, K. Stampfli
May 1998

...

Author Tag

...

Publisher Tag

...

Topic Tag

...

  • Alfred Hassig

  • Heinrich Kremer

  • Stefan Lanka

  • Liang Wen-Xi

  • Kurt Stampfli

...

  • CD4+

  • AIDS Drugs

    • Zidovudine

    • AZT

    • Protease Inhibitors

  • Surviving

    • Cure of AIDS

...

Published Year

...

Content Type

1998

...

  • Editorial article

...

The continuous failure in the prevention and treatment of AIDS is rooted in the misinterpretation of an inflammatory autoimmune process as a lethal, viral venereal disease

...

Dr. S. LANKA
Im Dreieck 8
D-44143 Dortmund
Germany (a-mail: lanka@free.de)

References:

Expand
titleClick here to expand..
  1. Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation ot a 1-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.

  2. Gallo RC, Salahuddin SZ, Popovic M et al. Frequent detection and Isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500-503

  3. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM. IS a positive western blot proof of HIV infection? Biotechnology NY 1 993;1 1:696-707.

  4. Lanka S. Fehldiagnose AIDS. Wechselwirkung l994;16:48-53.

  5. Lanka 5. HIV-Realität oder Artefakt? Raum und Zeit 1 995;77:1 7-27.

  6. Lanka 5. HIV - reality or artefact? Continuum 1995;3/1 :4-9.

  7. Papadopulos-Eleopulos E (Interview): Is HIV the cause of AlDS? Continuum 1997;5:8-19.

  8. Gluschankof P, Mondor 1, Gelderblom HR, Sattentau QJ. Cell membrane vesides are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virology 1997;230:1 25-1 33.

  9. Bess JW, Gorelick RJ, Bosche Wi, Henderson LE, Arthur LO. Microvesides are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 1997;230:1 34-144.

10. Ott DE, Coren LV, Kane BP et al. Cytosskeletal proteins inside human immunodeficiency virus type 1 virions. J Virol 1996;70:7734-7743.

11. Hässig A, Kremer H, Liang WX, Stampfil K. Offene Fragen zur Spezifität der Anti-HIV-Antik"rper. Schweiz Zschr GanzheitsMed 1 99 6;8(6): 294- 298.

12. Hässig A, Kremer H, Liang WX, Stampfil K. Parenteral übertragene Hepatitis-Viren und AIDS. Schweiz Zschr GanzheitsMed 1 996;8(7/8): 325-330.

13. Hässig A, Kremer H, Liang WX, Stampfli K. Hyperkatabole Krankheiten. Schweiz Zschr Ganzheitsmed 1 997;9(2):79-85.

14. Hässig A, Kremer H, Lanka St, Liang WX, Stampfli K. AIDS und Autoimmunität. Schweiz Zschr GanzheitsMed 1997;9(5):21 9-221.

15. George 1, Shoenfeld Y. Actin autoantibodies. In: Autoantibodies (Eds.: JP Peter, Y Shoenfeld). Amsterdam:Elsevier, 1 996:10-1 2.

16. Johnson GD, Holborow Ei, Glynn LE. Antibody to smooth muscle in patients with liver disease. Lancet 1965;ll:878-879

17. Gabbiani G, Ryan GB, Lamelin JP et al. Human smooth muscle auto antibody. Its identification as antiactin antibody and a study of itsbinding to ,,nonmuscular" cells. Am i Pathol 1 973;72:473-488.

18. Fagraeus A, Norberg R. Anti-actin antibodies. Curr bp Microbiot Immunol 1978;82:1-13.

19. Hamlyn AN, Berg PA. Haemagglutinating anti-actin antibodies in acute and chronic liver disease. Gut 1980;21:31 1-317.

20. Bermas BL, Petri M, Berzofsky JA, Waisman A, Shearer GM, Mozes E. Binding of glycoprotein 120 and peptides from HIV-1 envelope by auto antibodies in mice with experimentally induced systemic lupus ery- thematosus and in patients with the disease. AIDS Res Hum Retroviruses 1994;1O:1071-1077.

21. Weilandt C, Rotily M. European network on HIV/AIDS prevention in prisons. Final Report. Bonn, 1 997.

22. Störer H, Weilandt C. Pr"valenz viraler infektionskrankheiten und infektionsrelevantem Risikoverhalten im deutschen Justizvollzug. infektionsepidem Forsch 1997;6(II):22-27.

23. Meyenberg R, Störer H1 Jacob J et al. Infektionsprophylaxe im niedersächsischen Justizvollzug. Bibliotheks- und Informationssystem der Universität Oldenburg. Oldenburg, 1 996.

24. Girard D, Senecal JL. Anti-microfilament lgG antibodies in normal adults and in patients with autoimmune diseases; Immunofluorescence and immunoblotting analysis of 201 subjects reveals polyreactivity with microfilament-associated proteins. Clin Immunol Immunopathol 1995;74:193-201.

25. Strohman RC. Ihe coming Kuhnian revolution in biology. Nat Biotechnol 1997;1 5:194-200.

26. Temin HM, Mizutani 5. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 1970;226:1 211-1 21 3.

27. Temin HM, Baltimore D. RNA-directed DNA synthesis and RNA tumor viruses. Adv Virus Res 1972;1 7:129-186.

28. Temin HM. Reverse transcription in the eukaryotic genome: Retroviruses, pararetroviruses, retrotransposons, and retrotranscripts. Mol Bot Evol 1985;2:455-468.

29. Baltimore D. Retroviruses and retrotransposons: Ihe role of reverse transcription in shaping the eukaryotic genome. CelI 1985;40:481-482.

30. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Am 1996;274(2):80-85.

31. Boeke JD. DNA repair. A Jittle help for my ends. Nature 1996;383:579, 581.

32. Teng SC, Kirn B, Gasbriel A. Retrotransposon reverse-transcriptase- mediated repair of chromosomal breaks. Nature 1996;383:641-644.

33. Teng SC, Gabriel A. DNA repair by recycling reverse transcripts. Nature 1997;386:31-32.

34. Strahl C, Btackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996;16:53-65.

35. Yegorov YE, Chernov DN, Akimov 55, Bolsheva NL, Krayevsky AA, Zelenin AV. Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS fett 1 996;389:1 1 5-11 8.

36. Hässig A, Liang WX, Stampfli K. Reappraisal of the depletion of circutating CD4-lymphocytes in HJV-carriers in transition to AIDS. Continuum 1 996;3:1 8-20.

37. Carbonari M, Cibati M, Cherchi M et al. Detection and characterization of apoptotic peripheral blood Iymphocytes in human immunodeficiency virus infection and cancer chemotherapy by a novel flow immunocyto- metric method. Blood 1 994;83: 1 268-1 277.

38. Finkel TH, Tudor-Williams G, Banda NK et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995;1:129-134.

39. Fauci AS, Dale DC. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest 1 974;53:240-246.

40. Fauci AS, Dale DC. Ihe effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood 1 975;46:235-243.

41. Fauci AS, Pratt KR. Activation of human [3 lymphocytes. 1. Direct plaque-forming cell assay tor the measurement of polydonal activation and antigenic stimulation of human [3 lymphocytes. J Exp Med 1976;1 44:674-684.

42. Fauci AS, Pratt KR, Whalen G. Activation of human B lymphocytes. I. Cellular interactions in the PFC response of human tonsillar and penpheral blood [3 lymphocytes to polydonal activation by pokeweed mitogen. J Immunol 1976;1 17:2100-2104.

43. Haynes BF, Fauci AS. Activation of human B lymphocytes. III. Concanavalin A-induced generation of suppressor cells of the plaque-forming cell response of normal human B lymphocytes. J Immunol 1977; 118:2281-2287.

44. Fauci AS, Pratt KR, Whalen G. Activation of human B lymphocytes. III Regulatory effects of corticosteroids on the triggering signal in the plaque-forming cell response of human peripheral blood B lymphocytes to polydonal activation. J Immunol 1977;1 19:598-603.

45. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1 995;373:1 1 7-1 22.

46. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard iM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 1995;373:123-126.

47. Wolthers KC, Wisman GBA, Otto SA et al. T cell telomere length in HIV-1 infection: No evidence tor increased CD4~ T cell turnover. Science 1 996;274:1 543-1547.

48. Balter M. How does HIV overcome the body's T-ceIJ body guards? 11 th Colloquium of the Cent-Gardes, Marnes-la-Coquett~, France, 27 to 29 October, 1997. Science 1 997;278:1 399-1400.

49. Caivano SE. Hormonal mediation of immune dysfunction following thermal and traumatic injury. In: Advances in host defence mechanisms (Eds: ii Gallin, AS Fauci). Vol. 6. Nevv York:Raven, 1 986:111 - 142.

50. Wirthmüller U. Die Methode der PCR im Routinelabor. Haemo (Bern), 1997 (Juni):2-4. Wirthmüller U. Die Anwendung der quantitativen PCR in der Diagnostik und Behandlung von virologischen Erkrankungen. Haemo (Bern), 1997 (Dezember) :2-4.

51 Maniatis T, Fritsch EF7 SambrooI< J. Molecular cloning: A Iaboratory manual. New York: CoId Spring Harbor, 1 982.

52. Null G. AIDS - a second opinion. New York/London, 1997. (Video availabte at Continuum, 172 Foundling Court, Brunswick Centre, London WCIN 1 QE, UK.)

53. Hagen-Mann K, Mann W. Quantitative PCR. In: PCR im medizinischen und biologischen Labor. (Hrsg.: M. Wink, H. Werle.) Darmstadt:GIT 1 994: 84-96.

54. Schwartz DH, Laeyendecker OB, Arango-Jaramijjo 5, Castillo RC, Reynolds MJ. Extensive evaluation ot a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR. Lancet 1 997; 350:256-259.

55. Weber J. Distinguishing between response to HIV vaccine and response to HIV. Lancet 1997;350:230-231.

56. Dalakas MC, lila 1, Pezeshkpour GH, Laukaitis Mitochondrial myopathy caused by long-term N Engl J Med 1990;322:1098-1 105. J.P Cohen B, Griffin JL. zidovudine therapy.

57. Hayakawa M, Ogawa 1, Sugiyama S, Tanaka M, Ozawa T. Massive conversion of guanosine to 8-hydroxy-guanosine in mouse liver mitochondrial DNA by administration of azidothymidine. Biochem Biophys Res Commun 1991;176:87-93

58. Chariot P, Gherardi R. Partial cytochrome c oxidase deficiency and cytoplasmic bodies in patients with zidovudine myopathy. Neuromuscul Disorders 1991;1:357-363.

59. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-422.

60. Benbrik E, Chariot P, Bonavaud 5 et al. Cellutar and mitochondrial toxicity of zidovudine (AZI), didanosine (ddl) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997;149:19-25.

61. Habich D. HIV-Infektion und AIDS. Biologische Grundlagen und chemotherapeutische Ansätze. Chemie in unserer Zeit 1991 ;25:295-307.

62. Crixivan, Indinavir, MSD. Positiv l"nger leben. (Anzeige) Deutsche Aerztezeitung vom 21.11.97, 5.1 2.

63. Hässig A, Liang WX, Schwabl H, Stampfli K. Flavonoide und Tannine: Pflanzliche Antioxidanzien mit Vitamincharakter. Ueber die Bedeutung der nutritiven Zufuhr eines natürlichen Gemisches von Flavonoiden und Tanninen. Schweiz Zschr GesamtheitsMed 1997;9(4):1 71-1 75.

64. Hässig A, Rütte B von, Vettiger K. Zur Frage der Hepatitisübertragung durch Blut- und Plasmatranstusionen. Schweiz Med Wschr 1953;83: 487-492.

65. Dubs P, Fellmann H, Hässig A, Heim U, Portmann U, Schreiner W Zumstein P. Zur Frage der Hepatitisübertragung durch unltraviolett bestrahltes lyophilisiertes Mischplasma. Schweiz Wschr 1954;84: Med 1187-1192.

66. Hässig A, Heiz R, Stampfli K. Zur Prophylaxe von Hepatitisübertragungen bei Plasmatransfusionen. Schweiz Med Wschr 1955;85:614-61 5.

67. Brzosko WJ, iankowski A. PADMA 28 bei chronischer Hepatitis B; Klinische und immunologische Wirkungen. Schweiz Zschr GanzheitsMed 1992;4(Suppl.1 ):13-14.

68. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long- term HIV-1 infection without immunologic progression. AIDS 1994;8: 1123-1128.

69. Hoover DR, Rinaldo Ch, He Y, Phair J, Fahey J, Graham NMH. Long-term survival without c!inical AIDS after CD4- cell counts fall below 200 x 10 6/l. AIDS 1995;9:145-152.

70. Hogervorst E, Jurnaans S, Wolf F de et al. Predictors for non- and stow progression in human immunodeficiency virus (HIV) type 1 infection: Low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody leveis. J lnfect Dis 1995; 171:811-821.

71. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-208.

72. Pantaleo G, Menzo S, Vaccarezza M et al. Studies in subjects with long-term nonprogressive human 73. Harrer T, Harrer E, Kalams SA et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996;1 2:585-592.

74. Montefion DC, Pantaleo G, Fink LM et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in tong-term nonprogressors. J lnfect Dis 1 996;1 73:60-67.

75. Garbuglia AR, Salvi R, Di Caro A et al. In vitro activation of HIV RNA expression in peripheral blood Iymphocytes as a marker to predict the stability of non-progressive status in long-term survivors. AIDS 1996; 10:17-21.

76. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in Northern California: Results from a ten-year study. Am J Epidemiol 1997;1 46:350-357.